Bill Ackman’s Pershing Square Capital Management is having a tough time this year and he can partly thank Wall Street’s sell-side analysts for his woes. In the past few days, he has found himself on the opposite side of research recommendations on his two most controversial holdings—Herbalife and JC Penney. On Friday
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.